Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174?

Miller, Caela

425
Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174?

Sunday, March 29, 2015: 7:00 AM

Salon C-D (Hilton Chicago)

C. R. Miller¹, N. P. Chappell¹, C. A. Leath III², N. T. Phippen³, L. J. Havrilesky⁴ and J. C. Barnett¹
¹Brooke Army Medical Center, Fort Sam Houston, TX, ²University of Alabama at Birmingham, Birmingham, AL, ³Gynecologic Oncology Service, Department of Obstetrics and Gynecology, Murtha Cancer Center, Walter Reed National Military Medical Center, Bethesda, MD, ⁴Duke University Medical Center, Durham, NC

2015 Annual Meeting on Women's Cancer®

March 26 - 31, 2015

Navigation

425
Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174?

425 Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174?

425
Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174?